Carolyn K McCourt

6PUBLICATIONS
65CO-AUTHORS
Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 03, 2025
Targeting RAD52 overcomes PARP inhibitor resistance in preclinical Brca2-deficient ovarian cancer model.

Yukihide Ota, Vijayalaxmi Gupta, Bisiayo E Fashemi

|Jul 22, 2025
Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy-Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response.

Mark C Valentine, Mary M Mullen, Emilee N Kotnik

|Jun 27, 2025
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K.

Carolyn K McCourt, Zihan Wei, Kevin Kalinsky

|Mar 28, 2025
Comprehensive Molecular and Genomic Analysis of NCI-MATCH Subprotocol Y: Capivasertib in Patients With an AKT1 E17K-Mutated Tumor.

Carolyn K McCourt, Jacob Gross, Kevin Kalinsky

|Aug 01, 2023
Stromal DDR2 Promotes Ovarian Cancer Metastasis through Regulation of Metabolism and Secretion of Extracellular Matrix Proteins.

Angela M Schab, Molly M Greenwade, Elizabeth Stock

|Apr 25, 2023
RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer.

Amanda J Compadre, Lillian N van Biljon, Mark C Valentine

Pageof 1

Frequent Collaborators

4 joint publications

Andrea R Hagemann

4 joint publications

Lindsay M Kuroki

3 joint publications

Matthew A Powell

3 joint publications

David G Mutch